{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:37:16Z","timestamp":1774597036797,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lineage plasticity has emerged as an important mechanism of treatment resistance in prostate cancer, increasingly associated with loss of androgen receptor (AR) signaling, and in many cases induction of stemness phenotypes and neuroendocrine features. However, targeted therapies for this stage of the disease are currently lacking. In this study, we demonstrated the critical role of the epigenetic regulator UHRF1 in the enzalutamide resistance development of prostate cancer. We have shown that UHRF1 is highly expressed in enzalutamide-resistant prostate cancer cells and its expression correlates with the loss of AR-dependent glandular features. Knocking down UHRF1 led to increased AR expression and enhanced the activity of canonical AR signaling pathway in prostate cancer cells. The combination of UHRF1 knockdown with enzalutamide treatment demonstrated synergistic tumor inhibitory effects both in vitro and in vivo. Mechanistically, UHRF1 was found to bind to AR and promote its ubiquitination and degradation. Furthermore, inhibition of UHRF1 restored AR pathway activity and re-sensitized resistant prostate cancer cells to enzalutamide. Therefore, our findings elucidate an intracellular molecular mechanism that promotes prostate cancer lineage plasticity and suggest that UHRF1 may serve as a potential therapeutic target for overcoming resistance to AR-targeted therapies.<\/jats:p>","DOI":"10.1038\/s41419-026-08511-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:35:46Z","timestamp":1772202946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UHRF1 regulates AR ubiquitination to promote the loss of AR signaling and enzalutamide resistance in progression of prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-3412","authenticated-orcid":false,"given":"Yifan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangsang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiapeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-7697","authenticated-orcid":false,"given":"Shidong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-6922","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-1603","authenticated-orcid":false,"given":"Hailiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"8511_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet (Lond, Engl). 2016;387:70\u201382.","journal-title":"Lancet (Lond, Engl)"},{"key":"8511_CR2","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res: Off J Am Assoc Cancer Res. 2019;25:6916\u201324.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"8511_CR3","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Investig. 2019;129:4492\u2013505.","journal-title":"J Clin Investig"},{"key":"8511_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41556-021-00744-4","volume":"23","author":"L Xin","year":"2021","unstructured":"Xin L. EZH2 accompanies prostate cancer progression. Nat Cell Biol. 2021;23:934\u20136.","journal-title":"Nat Cell Biol"},{"key":"8511_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29963-5","volume":"13","author":"S Nouruzi","year":"2022","unstructured":"Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, et al. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 2022;13:2282.","journal-title":"Nat Commun"},{"key":"8511_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021;23:1023\u201334.","journal-title":"Nat Cell Biol"},{"key":"8511_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9:2404.","journal-title":"Nat Commun"},{"key":"8511_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.apsb.2025.01.007","volume":"15","author":"X Zhang","year":"2025","unstructured":"Zhang X, Yang Y, Zou H, Yang Y, Zheng X, Corey E, et al. Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors. Acta Pharm Sin B. 2025;15:1415\u201329.","journal-title":"Acta Pharm Sin B"},{"key":"8511_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","volume":"86","author":"S Liu","year":"2022","unstructured":"Liu S, Alabi BR, Yin Q, Stoyanova T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022;86:57\u201368.","journal-title":"Semin Cancer Biol"},{"key":"8511_CR10","doi-asserted-by":"publisher","first-page":"26.","DOI":"10.3390\/epigenomes8030026","volume":"8","author":"A Kim","year":"2024","unstructured":"Kim A, Benavente CA. Oncogenic roles of Uhrf1 in cancer. Epigenomes. 2024;8:26.","journal-title":"Epigenomes"},{"key":"8511_CR11","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1093\/nar\/gkab293","volume":"49","author":"M Mancini","year":"2021","unstructured":"Mancini M, Magnani E, Macchi F, Bonapace IM. The multi-functionality of UHRF1: epigenome maintenance and preservation of genome integrity. Nucleic Acids Res. 2021;49:6053\u201368.","journal-title":"Nucleic Acids Res"},{"key":"8511_CR12","doi-asserted-by":"publisher","first-page":"e202210093.","DOI":"10.1083\/jcb.202210093","volume":"222","author":"X Qi","year":"2023","unstructured":"Qi X, Liu Y, Peng Y, Fu Y, Fu Y, Yin L. et al. UHRF1 promotes spindle assembly and chromosome congression by catalyzing EG5 polyubiquitination. J. Cell Biol. 2023;222:e202210093.","journal-title":"J. Cell Biol"},{"key":"8511_CR13","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1038\/onc.2011.641","volume":"31","author":"F Babbio","year":"2012","unstructured":"Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, et al. The sra protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene. 2012;31:4878\u201387.","journal-title":"Oncogene"},{"key":"8511_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41422-021-00565-y","volume":"32","author":"X Xu","year":"2022","unstructured":"Xu X, Ding G, Liu C, Ding Y, Chen X, Huang X, et al. Nuclear UHRF1 is a gate-keeper of cellular AMPK activity and function. Cell Res. 2022;32:54\u201371.","journal-title":"Cell Res"},{"key":"8511_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1191311","volume":"14","author":"J Imamura","year":"2023","unstructured":"Imamura J, Ganguly S, Muskara A, Liao RS, Nguyen JK, Weight C, et al. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Front Endocrinol (Lausanne). 2023;14:1191311.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8511_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26840-5","volume":"12","author":"M Bolis","year":"2021","unstructured":"Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Impellizzieri D, et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun. 2021;12:7033.","journal-title":"Nat Commun"},{"key":"8511_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","volume":"3","author":"T Chu","year":"2022","unstructured":"Chu T, Wang Z, Pe\u2019er D, Danko CG. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat Cancer. 2022;3:505\u201317.","journal-title":"Nat Cancer"},{"key":"8511_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Sci (NY, NY). 2009;324:787\u201390.","journal-title":"Sci (NY, NY)"},{"key":"8511_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/cr.2015.72","volume":"25","author":"W Qin","year":"2015","unstructured":"Qin W, Wolf P, Liu N, Link S, Smets M, La Mastra F, et al. DNA methylation requires a DNMT1 ubiquitin-interacting motif (uim) and histone ubiquitination. Cell Res. 2015;25:911\u201329.","journal-title":"Cell Res"},{"key":"8511_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ejmech.2016.02.043","volume":"114","author":"V Myrianthopoulos","year":"2016","unstructured":"Myrianthopoulos V, Cartron PF, Liutkevi\u010di\u016bt\u0117 Z, Klima\u0161auskas S, Matulis D, Bronner C, et al. Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating dna methylation. Eur J Med Chem. 2016;114:390\u20136.","journal-title":"Eur J Med Chem"},{"key":"8511_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"8511_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00430-6","volume":"11","author":"SC Wu","year":"2022","unstructured":"Wu SC, Kim A, Gu Y, Martinez DI, Zocchi L, Chen CC, et al. UHRF1 overexpression promotes osteosarcoma metastasis through altered exosome production and AMPK\/sema3e suppression. Oncogenesis. 2022;11:51.","journal-title":"Oncogenesis"},{"key":"8511_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2021.07.012","volume":"520","author":"Y Gao","year":"2021","unstructured":"Gao Y, Liu Y, Liu Y, Peng Y, Yuan B, Fu Y, et al. UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-mediated chromatin modifications. Cancer Lett. 2021;520:172\u201383.","journal-title":"Cancer Lett"},{"key":"8511_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00446-y","volume":"12","author":"Y Fu","year":"2023","unstructured":"Fu Y, Cao T, Zou X, Ye Y, Liu Y, Peng Y, et al. AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. Oncogenesis. 2023;12:1.","journal-title":"Oncogenesis"},{"key":"8511_CR25","first-page":"189","volume":"2","author":"EB Blatt","year":"2019","unstructured":"Blatt EB, Raj GV. Molecular mechanisms of enzalutamide resistance in prostate cancer. Cancer drug resistance (Alhambra, Calif.). 2019;2:189\u201397.","journal-title":"Cancer drug resistance (Alhambra, Calif.)"},{"key":"8511_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/nar\/gki141","volume":"33","author":"L Gaughan","year":"2005","unstructured":"Gaughan L, Logan IR, Neal DE, Robson CN. Regulation of androgen receptor and histone deacetylase 1 by MDM2-mediated ubiquitylation. Nucleic Acids Res. 2005;33:13\u201326.","journal-title":"Nucleic Acids Res"},{"key":"8511_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41374-021-00716-0","volume":"102","author":"X Shui","year":"2022","unstructured":"Shui X, Xu R, Zhang C, Meng H, Zhao J, Shi C. Advances in neuroendocrine prostate cancer research: from model construction to molecular network analyses. Lab Investig; a J Tech methods Pathol. 2022;102:332\u201340.","journal-title":"Lab Investig; a J Tech methods Pathol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08511-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08511-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:40:47Z","timestamp":1774593647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08511-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8511"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08511-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (No. NFEC-2022-299). Written informed consent was obtained from all patients for the use of their tumor tissue samples and clinical data for research purposes. Patient-derived clinical data were fully anonymized with encrypted storage separating personally identifiable information from research datasets. For the animal experiments, all procedures were carried out in accordance with the recommendations of the Southern University of Science and Technology Laboratory Animal Welfare Ethics Review Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"286"}}